Multiparameter Affinity Microchip for Early Sepsis Diagnosis Based on CD64 and CD69 Expression and Cell Capture

Area of Science:

• Biomedical Engineering
• Immunology
• Clinical Diagnostics

Background:

• Sepsis is a life-threatening condition with high global mortality rates.
• Delayed diagnosis and treatment of sepsis contribute significantly to patient mortality.
• Current diagnostic methods can be time-consuming, hindering prompt intervention.

Purpose of the Study:

• To develop and validate a multiparameter affinity microchip for rapid sepsis diagnosis.
• To assess the microchip's ability to differentiate between septic and healthy individuals.
• To evaluate the diagnostic performance of specific cell surface markers in sepsis.

Main Methods:

• Development of a microfluidic device with discrete antibody regions for cell capture.
• Separation and quantification of cells expressing CD25, CD64, and CD69.
• Comparison of microchip performance with traditional flow cytometry.
• Validation using blood samples from septic patients and healthy volunteers.

Main Results:

• The microchip demonstrated linear correlation between cell counts and antigen expression levels (CD64, CD69).
• Statistically significant differences in cell capture were observed between septic and healthy samples (p=0.0033 for CD64, p=0.0221 for CD69).
• High diagnostic performance was achieved, with an Area Under the Curve (AUC) of 0.98 when combining CD64 and CD69 markers.

Conclusions:

• The multiparameter affinity microchip enables rapid and accurate sepsis diagnosis.
• The microchip effectively distinguishes septic patients based on specific leukocyte surface marker expression.
• Combining multiple markers (CD64, CD69) significantly enhances diagnostic performance for sepsis.